SITC’s Guide to Managing Immunotherapy Toxicity (eBook)

Marc Ernstoff, Igor Puzanov, Caroline Robert, Adi Diab, Peter Hersey (Herausgeber)

eBook Download: EPUB

2019
250 Seiten
Springer Publishing Company (Verlag)
978-0-8261-7215-0 (ISBN)

Infos

The Society for Immunotherapy of Cancer's handbook,SITC's Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers.With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care.Key Features:Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapyProvides numerous tables that condense and highlight pertinent information for quick referenceDescribes the various clinical presentations and toxic reactions caused by immunotherapyPurchase includes access to the eBook for use on most mobile devices or computer

Inhalt

Foreword

Introduction

Part 1: Immune Checkpoint Inhibitors in the Clinic

Chapter One: Overview of Anti-CTLA-4 Agents: Ipilimumab and Tremilimumab

Daniel Hartman Johnson and Jianjun Gao

Chapter Two: Overview of PD-1 and PD-L1 Inhibitors

Nikolaos Andreatos, Shailender Bhatia, and Petros Grivas

Chapter Three: Indications and Toxicities of Immune Checkpoint Inhibitor Combinations

Lavinia Spain, Michael A. Postow, James Larkin, and Jeffrey Weber

Part 2: Specific Immune Checkpoint Inhibitor Toxicities

Chapter Four: General Principles of Immune-Related Toxicities

Osama E. Rahma and Patrick A. Ott

Chapter Five: Dermatological Toxicities: Rash, Mucosal Irritation, and Pruritus

Jennifer Wu and Mario E. Lacouture

Chapter Six: Musculoskeletal and Rheumatologic Toxicities

Noha Abdel-Wahab, Clifton O. Bingham III, and Maria Suarez-Almazor

Chapter Seven: Immune-Related Gastrointestinal Toxicities

Hamzah Abu-Sbeih, Daniel Johnson, Yinghong Wang

Chapter Eight: Pneumotoxicity Associated with Immune Checkpoint Blockades

Vickie R. Shannon

Chapter Nine: Immune-Related Endocrinopathies Associated with Immune Checkpoint Inhibitors

Rajeev Sharma, Ha Nguyen, Ramona Dadu

Chapter Ten: Neurologic Adverse Events and Neurologic Complications

Haroon Ahmad, Jasmin Jo, Elizabeth Gaughan, Camilo Fadul

Chapter Eleven: Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors

Pankit Vachhani, Igor Puzanov, Javid J. Moslehi

Chapter Twelve: Renal Toxicities Associated with Immune Checkpoint Inhibitors

Ala Abudayyeh, Maen Abdelrahim, Laurence Albiges

Chapter Thirteen: Hematologic Toxicities of Apparent Immune-Related Origins

George L. Chen, Caroline Robert, Alexander M. Lesokhin

Chapter Fourteen: Ocular Toxicities Caused by Immune Dysregulation

Liliya Golas and Dimitra Skondra

Chapter Fifteen: Safety and Regulation of Immune Checkpoint Inhibitors in Special Patient Populations

Douglas B. Johnson, Ryan Sullivan, Paolo A. Ascierto

Chapter Sixteen: Cancer-Related Fatigue in Patients of Immune Checkpoint Inhibitor Therapy

Eric D. Hansen, Michelle Walter, Amy A. Case

Chapter Seventeen: Cost Effectiveness and Financial Toxicity in New Cancer Therapies

Christine Kohn, Natalia Shcherbakova, Alberto J. Montero

Produkt-Details

• Erscheint lt. Verlag: 15.3.2019
• Sprache: englisch
• Maße: 130 x 130 mm
• Themenwelt: Medizin / Pharmazie ► Allgemeines / Lexika
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
• Themenwelt: Studium ► Querschnittsbereiche ► Infektiologie / Immunologie
• Schlagworte: Anticancer activity • Clinicians • Common Terminology Criteria for Adverse Events • cost-effective strategies • Cytotoxic Chemotherapy • cytotoxic treatment • dose-limiting toxicity • evidence-based decisions • host immune system • immune-related adverse events • The Society for Immunotherapy of Cancer • Tumor immunotherapy
• ISBN-10: 0-8261-7215-6 / 0826172156
• ISBN-13: 978-0-8261-7215-0 / 9780826172150